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Early Activation of the Kynurenine Pathway Predicts Early Death and
Long-term Outcome in Patients Resuscitated From Out-of-Hospital
Cardiac Arrest
Giuseppe Ristagno, MD, PhD; Roberto Latini, MD; Jukka Vaahersalo, MD; Serge Masson, PhD; Jouni Kurola, MD, PhD; Tero Varpula, MD,
PhD; Jacopo Lucchetti, MBiol; Claudia Fracasso, MBiol; Giovanna Guiso, MBiol; Alessandro Montanelli, MD; Simona Barlera, MSc;
Marco Gobbi, PhD; Marjaana Tiainen, MD, PhD; Ville Pettil€a, MD, PhD; Markus B. Skrifvars, MD, PhD, EDIC, FCICM; for the FINNRESUSCI
Investigators*
Background-—The kynurenine pathway (KP) is the major route of tryptophan (TRP) catabolism and is activated by inﬂammation and
after cardiac arrest in animals. We hypothesized that the KP activation level correlates with severity of post–cardiac arrest shock,
early death, and long-term outcome.
Methods and Results-—Plasma was obtained from 245 patients enrolled in a prospective multicenter observational study in 21
intensive care units in Finland. Time to return of spontaneous circulation, lowest systolic arterial pressure, and bicarbonate during
the ﬁrst 24 hours were collected. A cerebral performance category of 3 to 5 deﬁned 12-month poor outcome. Plasma TRP and KP
metabolites, kynurenine (KYN), kynurenic acid, 3-hydroxyanthranilic acid, and the ratio of KYN to TRP were measured by liquid
chromatography and mass spectrometry. All KP metabolites at intensive care unit admission were signiﬁcantly higher in cardiac
arrest patients with a nonshockable rhythm compared to those with a shockable rhythm, and kynurenic acid and 3-
hydroxyanthranilic acid correlated with time to return of spontaneous circulation. Patients with higher levels of KYN, KYN to TRP,
kynurenic acid, and 3-hydroxyanthranilic acid had lower 24-hour systolic arterial pressure and bicarbonate. All KP metabolites and
the ratio of KYN to TRP, but not TRP, were signiﬁcantly higher in patients who died in the intensive care unit in comparison to those
who survived. Multivariable logistic regression showed that high kynurenic acid (odds ratio: 1.004; 95% conﬁdence interval: 1.001
to 1.008; P=0.014), and 3-hydroxyanthranilic acid (odds ratio: 1.011; 95% conﬁdence interval: 1.001 to 1.022; P=0.03) were
independently associated with 12-month poor outcome and signiﬁcantly improved risk reclassiﬁcation.
Conclusions-—KP is activated early after cardiac arrest and is associated with severity of post–cardiac arrest shock, early death,
and poor long-term outcome. ( J Am Heart Assoc. 2014;3:e001094 doi: 10.1161/JAHA.114.001094)
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D espite initially successful resuscitation, morbidity andmortality following cardiac arrest (CA) remain high.1 The
pathophysiological state recently named “post–cardiac arrest
syndrome” is characterized by myocardial dysfunction with
circulatory shock, systemic inﬂammation with activation of
the clotting system, and evolving brain injury.2,3 Accordingly,
there are evident similarities between sepsis, septic shock,
and post-CA syndrome.4 On reperfusion following CA, a
possible sequence of events includes a systemic inﬂammatory
response that contributes to worsening of circulatory shock
and neurological injury.2,4
Recently, the activation of the enzyme indoleamine 2,3-
dioxygenase, which is responsible for the metabolism of the
essential amino acid tryptophan (TRP) to kynurenine (KYN)—
the ﬁrst step of the so-called kynurenine pathway (KP)—has
been highlighted in septic shock patients.5 The activation of
this pathway results in increased levels of KYN, which in turn
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cause vasodilatation.5 Interestingly, KP activation has also
been implicated in instances accounting for neurological
injury (ie, stroke and cerebral dysfunction) in intensive care
unit (ICU) patients and in adverse prognosis in patients with
coronary artery disease.6–8 Downstream metabolites of KP
include kynurenic acid (KYNA) and 3-hydroxyanthranilic acid
(3-HAA)9–11; the former has neuroprotective properties,
whereas the latter has been associated with neurological
damage and apoptosis of neurons.11,12 Thus, these 2 KP
metabolites have been implicated in the pathogenesis of
evolving neurological injury after an ischemic insult.6
In a study including both small and large animal models of
CA and cardiopulmonary resuscitation, we recently demon-
strated the early activation of the KP after successful
resuscitation.13 In the present observational cohort study,
we examined the KP in a large population of patients
resuscitated from out-of-hospital CA. We hypothesized that
the KP is activated after CA and that high levels of activation
at ICU admission are associated with severity of post-CA
hypotension, early death, and poor 12-month neurological
outcome.
Methods
Patients
Patients included in the present study were part of the
Epidemiology and Cost-effectiveness of Out-Of-Hospital Car-
diac Arrest in Finland (FINNRESUSCI) study, which was a
prospective observational cohort study conducted at 21
hospitals in Finland between March 1, 2010, and February 28,
2011.14 The study was approved by the ethics committee of
each participating hospital. Informed consent from the
patients’ next of kin was obtained for data collection and
blood sampling. For this study, we included patients with both
shockable and nonshockable initial rhythms in whom blood
samples were obtained at ICU admission. Blood was also
drawn from 10 healthy volunteers matched for age and sex
with the study population.
Blood Samples
Blood samples were collected into EDTA tubes and centri-
fuged, and plasma was stored at 70°C. At analysis, samples
were thawed and divided into aliquots. Plasma levels of TRP
and its metabolites, KYN, KYNA, and 3-HAA, were measured
blinded to case identity using high-performance liquid chro-
matography coupled with mass spectrometry. We used blood
samples from healthy subjects to serve as controls. Brieﬂy,
human plasma samples (100 lL) were mixed with 10 lL of
internal standard (5-HTRP, 1 ng/lL or deuterated metabolites
[TRP-d5, 12 ng/lL; KYNA-d4, 0.4 ng/lL; KYNA-d5,
0.012 ng/lL; 3-HAA-d2, 0.012 ng/lL], ﬁnal concentrations)
that was deproteinized by adding 400 lL of cold methanol
and incubated for 1 hour at 20°C. After centrifugation for
10 minutes at 14 000g, the supernatants were collected and
centrifuged again. Supernatants were dried under nitrogen
ﬂow; residues were dissolved in 100 lL of 1% acetonitrile in
0.1% formic acid and transferred to an autosampler vial insert,
and 40 lL of supernatant was injected directly in the high-
performance liquid chromatography system (Alliance separa-
tions module 2695; Waters Corp). The chromatographic
separation was obtained with an Accucore PFP column
(15092.1 mm, 2.6-lm particle size; Thermo-Scientiﬁc) at a
ﬂow rate of 0.2 mL/min. Elution started with 99% of mobile
phase A (0.1% formic acid in water) and 1% mobile phase B
(100% acetonitrile) for 2 minutes, followed by an 18-minute
linear gradient to 50% of phase A, a 1-minute linear gradient
to 30% of phase A, and a 1-minute linear gradient to 99% of
phase A, which was maintained for 12 minutes to equilibrate
the column. The total run time was 35 minutes. The mass
spectrometric analysis was performed using a Micromass
Quattro Micro API triple-quadrupole (Waters Corp) in positive
ion mode and multiple-reaction monitoring mode, measuring
the fragmentation products of the deprotonated pseudomo-
lecular ions. The choice of fragmentation products for all
compounds and the optimization of collision-induced dissoci-
ation energies were done in continuous-ﬂow mode using
standard solutions at concentrations of 10 ng/lL for all
compounds. Data were processed with the MassLynx soft-
ware (Waters Corp). Plasma concentrations of TRP and KP
metabolites were quantiﬁed by reference to 5-point calibra-
tion curves that were always run in parallel and that were
linear over the used concentration ranges (15 to 118 lmol/L
for TRP, 0.4 to 3.8 lmol/L for KYN, 16 to 127 nmol/L for
KYNA, and 20 to 157 nmol/L for 3-HAA). The r2 values were
always >0.95. The limit of detection (ie, 3 times the
background) was 1 nmol/L for TRP, KYN, and KYNA and
10 nmol/L for 3-HAA. The quality of analytical results was
checked by assaying quality-control samples, which were
always within 20% error. Plasma concentrations of TRP and
KYN were expressed in micromolar, and KYNA and 3-HAA
were expressed in nanomolar.
Plasma levels of C-reactive protein were measured using
the latex immunoassay CRP Vario -high-sensitivity method
with the Ci16200 Architect instrument (Abbott Diagnostics,
USA).
Data Collection
The participating hospitals were part of the Finnish Intensive
Care Consortium, and 20 of 21 ICUs used the same electronic
data management system and data validation software (Web
Validator; Tieto Corp). Data from study patients were
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collected prospectively using an Internet-based case report
form. Prehospital data were collected by the paramedics in
accordance with the Utstein Style guidelines and included
whether or not the arrest was witnessed, the administration of
bystander-initiated life support, the time from call to the
dispatch center to return of spontaneous circulation (ROSC),
and the use of adrenaline.15 In-hospital care data were
collected electronically and comprised the Simpliﬁed Acute
Physiology Score II score and ICU and hospital mortality. For
the present trial, we used Simpliﬁed Acute Physiology Score II
score–derived systolic blood pressure and bicarbonate to
deﬁne the severity of post-CA shock.
Survival and 12-Month Neurological Outcome
Time of death was recorded for each patient. A specialist in
neurology (M.T.) blinded to management in the ICU contacted
patients discharged from the hospital by phone 1 year after
CA and determined neurological outcome according to the
Pittsburgh Cerebral Performance Categories14; we deﬁned 12-
month good outcome as category 1 or 2 and 12-month poor
outcome as categories 3–5.
Statistical Analysis
Baseline characteristics by outcome occurrence were com-
pared by chi-square test in case of categorical variables or
by t test or nonparametric Wilcoxon test for continuous
variables. Comparison in baseline characteristics and KP
variables between healthy volunteers and study patients were
performed by Fisher chi-square test or by Wilcoxon test. When
the subgroups of ICU death and ICU survival were compared
with healthy volunteers, adjustment for the 2 contrasts was
applied. Median values with interquartile ranges (IQRs) were
calculated for KP metabolites. Levels of KP metabolites across
variables at admission were compared by the Wilcoxon test
and the Kruskal-Wallis test, and changes over time were
analyzed using the Wilcoxon signed rank test for paired data.
Multivariable linear regression was used to identify the
independent factors at resuscitation inﬂuencing metabolite
levels at ICU admission. Results of linear regression are
reported in terms of b coefﬁcients with 95% CIs and P values.
Multivariable logistic regression was used to identify factors
at resuscitation that were predictors of ICU mortality and poor
outcome at 12 months from the arrest. All variables associ-
ated with the outcome in the univariate analysis (P<0.05)
were included in the multivariable model. Each KP metabolite
was included separately in the model as a continuous
variable. Odds ratios (ORs) with the corresponding 95% CIs
were calculated, and P values were considered statistically
signiﬁcant if they were <0.05. The addition of new predictive
variables (ie, KP metabolites) into a model containing clinical
risk factors (basic model) was assessed by comparing the
area under the curve by DeLong comparison.16 The increase
in the discriminative value of each KP metabolite for ICU
mortality and long-term outcome was assessed by the
category-free Net Reclassiﬁcation Index.17 All statistical
analyses were performed with SAS software, version 9.2
(SAS Institute).
Results
The FINNRESUSCI study included 548 patients.14 Among
these, informed consent for blood sampling at ICU admission
was obtained for 245 patients, and all were included in the
study. Differences between these 245 patients and the 303
not included because of the absence of the blood sample
and/or consent are reported in Table 1. Of the 245 patients
included in the study, 198 (81%) survived to ICU discharge,
144 (59%) survived to hospital discharge, and 124 (51%) were
alive at 12 months. Of the 124 patients who survived to
12 months, 116 (94% of survivors and 47% of the total 245
resuscitated patients) had a favorable neurological outcome
(Pittsburgh Cerebral Performance Category 1 or 2) at
12 months.
Among the 245 patients, 156 (64%) had a CA with an initial
shockable rhythm, whereas 88 (36%) were nonshockable
(data on initial rhythm was missed for 1 patient). Among the
shockable CA patients, 140 (90%) survived to ICU discharge
and 93 (60%) had a good 12-month neurological outcome.
Among the nonshockable CA patients, 58 (66%) survived to
ICU discharge and 23 (26%) had a good 12-month neurolog-
ical outcome. Baseline characteristics and factors inﬂuencing
ICU survival and 12-month outcome are shown in Table 2.
Prehospital factors univariately associated with higher likeli-
hood of ICU survival and 12-month outcome were younger
age, a shockable initial rhythm, witnessed CA, no use of
adrenaline, and a shorter time to ROSC (Table 2).
KP Metabolites and Factors Related to
Resuscitation
The median levels of TRP and KP metabolites in the 10 healthy
volunteers were comparable to those in the literature (TRP:
82.8 lmol/L [IQR: 70.0 to 89.0]; KYN: 2.4 lmol/L [IQR: 2.3
to 2.9]; KYN/TRP: 0.03 [IQR: 0.027 to 0.034]; KYNA:
40.6 nmol/L [IQR: 32.5 to 60.3]; 3-HAA: 24.3 nmol/L [IQR:
18.1 to 27.8]).6,18 There were no differences in the basic
characteristics between the healthy volunteers and the
resuscitated patients (Table 3). TRP was signiﬁcantly lower
and the ratio of KYN to TRP was signiﬁcantly higher in all
resuscitated patients compared with healthy volunteers.
When patients who did not survive to ICU discharge were
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considered, all KP metabolites and the ratio of KYN to TRP
were signiﬁcantly higher compared with healthy volunteers
(Table 3).
At ICU admission, median KP metabolite values were as
follows: TRP: 39.5 lmol/L (IQR: 30.8 to 50.4); KYN:
2.6 lmol/L (IQR: 1.8 to 3.5); KYN/TRP: 0.064 (IQR: 0.045
to 0.089); KYNA: 52.8 nmol/L (IQR: 27.5 to 91.8); 3-HAA:
28.1 nmol/L (IQR: 17.5 to 51.2). At ICU admission, the levels
of KYN, KYN to TRP, and KYNA were higher in older patients
(Table 4). All KP metabolites were also signiﬁcantly higher,
except for TRP and KYNA, which were signiﬁcantly lower, in
patients with an initial nonshockable rhythm compared with
those with a shockable rhythm (Table 4). Longer time to
ROSC accounted for signiﬁcantly higher levels of KYNA and
3-HAA (Table 4). By linear regression models, presence of a
shockable rhythm and use of adrenaline were the main
independent predictors of levels of KP metabolites, as
detailed in Table 5.
On average, plasma C-reactive protein levels were 2.8 mg/
L (IQR: 1.2 to 8.9), with no difference between patients who
survived to ICU (2.8 mg/L [IQR: 1.2 to 8.3]) and those who
died (2.8 mg/L [IQR: 1.2 to 23], P=0.488).
Correlations Between KP Metabolites and
Severity of Shock
Levels of all KP metabolites and KYN to TRP at ICU admission
were signiﬁcantly higher in patients who had lower systolic
Table 1. Baseline Characteristics and Clinical Factors at Resuscitation Between Patients With a Blood Sample and Included in the
Analysis and Those Without a Blood Sample and Not Included in the Analysis
Characteristic Patients With Blood Sample (n=245) Patients Without Blood Sample (n=303) P Value
Age, y, median (IQR) 63 (53 to 72) 63 (56 to 72) 0.566
Sex, male, n (%) 197 (80) 217 (72) 0.013
Shockable rhythm, n (%) 156 (64) 152 (50) 0.001
Witnessed cardiac arrest, n (%) 222 (91) 267 (88) 0.437
BLS, n (%) 140 (57) 152 (50) 0.112
Adrenaline used, n (%) 163 (67) 201 (69) 0.822
Time to ROSC, min, median (IQR) 20 (13 to 28) 20 (13 to 27) 0.935
Therapeutic hypothermia, n (%) 176 (72) 135 (45) 0.001
SAPS II score, median (IQR) 60 (47 to 69) 59 (44 to 68) 0.691
ICU survival, n (%) 198 (81) 231 (76) 0.196
12-month survival, n (%) 124 (51) 123 (40) 0.001
Good outcome at 12 months, n (%) 116 (47) 97 (32) 0.001
BLS indicates bystander-initiated basic life support; ICU, intensive care units; IQR, interquartile range; ROSC, return of spontaneous circulation; SAPS II, Simpliﬁed Acute Physiology
Score II.
Table 2. Baseline Characteristics and Clinical Factors at Resuscitation Between ICU Survivors and Nonsurvivors and Patients With
Good and Poor Outcome at 12 Months
Characteristic ICU Survival (n=198) ICU Death (n=47) Good Outcome at 12 Months (n=116) Poor Outcome at 12 Months (n=128)
Age, median (IQR) 63 (56 to 72) 65 (59 to 75) 61 (53 to 67)§ 66 (59 to 75)
Sex, male, n (%) 159 (80) 38 (81) 92 (79) 105 (82)
Shockable rhythm, n (%) 140 (71)** 16 (34) 93 (80)§ 63 (50)
Witnessed cardiac arrest, n (%) 182 (92) 40 (85) 111 (96)§ 110 (86)
BLS, n (%) 117 (59) 23 (49) 73 (63)† 67 (52)
Adrenaline used, n (%) 120 (61)** 43 (91) 55 (48)§ 107 (84)
Time to ROSC, min, median (IQR) 19 (12 to 26)** 24 (20 to 31) 16 (11 to 22)§ 24 (18 to 31)
Therapeutic hypothermia, n (%) 149 (75)* 27 (57) 89 (77) 87 (68)
†Data on 1-year outcome was missed for 1 patient. *P<0.05 and **P<0.01 vs ICU death; §P<0.01 vs poor outcome at 12 months. BLS indicates bystander-initiated basic life support;
ICU, intensive care units; IQR, interquartile range.
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blood pressure and lower levels of bicarbonate during the
subsequent 24 hours after ROSC (Table 4).
KP Metabolites at ICU Admission and Outcome
All KP metabolites except TRP correlated with ICU death
(Figure 1) and with 12-month death and neurological outcome
(Figure 2 and Table 4). Levels of all KP metabolites and the
ratio of KYN to TRP were signiﬁcantly higher in patients who
died compared with those who survived (Figures 1 and 2) and
in patients with poor outcomes at 12 months compared with
those with good outcomes (Table 4). The ORs for prediction of
ICU mortality were 0.982 (95% CI: 0.959 to 1.004 per lmol/L
increase; P=0.11) for TRP, 1.589 (95% CI: 1.287 to 1.963 per
lmol/L increase; P<0.0001) for KYN, 2.284 (95% CI: 1.518 to
3.438 per 1 SD increase; P<0.0001) for ratio of KYN to TRP,
1.004 (95% CI: 1.002 to 1.007 per nmol/L increase;
P=0.0003) for KYNA, and 1.019 (95% CI: 1.010 to 1.027
per nmol/L increase; P<0.0001) for 3-HAA. The ORs for the
prediction of 12-month poor outcome were 0.987 (95% CI:
0.970 to 1.004 per lmol/L increase; P=0.15) for TRP, 1.529
(95% CI: 1.233 to 1.896 per lmol/L increase; P=0.0001) for
KYN, 2.569 (95% CI: 1.560 to 4.231 per 1 SD increase;
P=0.0002) for ratio of KYN to TRP, 1.004 (95% CI: 1.001 to
1.007 per nmol/L increase; P=0.006) for KYNA, and 1.017
(95% CI: 1.008 to 1.027 per nmol/L increase; P=0.0002) for
3-HAA.
We developed multivariable models for the prediction of
ICU mortality and 12-month poor outcome. The clinical (basic)
model for prediction of ICU death included the initial CA
rhythm (shockable or nonshockable), time to ROSC, use of
adrenaline, and whether or not therapeutic hypothermia was
applied (Table 2). Each of the KP metabolites and the ratio of
KYN to TRP, but not TRP, were independently associated with
ICU death when added to the basic model (Table 6). The
addition of each KP metabolite to the basic model improved
the prognostic discrimination for ICU death, signiﬁcantly
increasing the area under the receiver operating characteristic
curve, and reclassiﬁcation, estimated by category-free net
reclassiﬁcation index. Comparison between the areas under
the curve of the basic model and those of the incremental
models are reported in Table 7, together with the category-
free net reclassiﬁcation index for each KP metabolite.
The basic model for prediction of poor outcome at
12 months included age, whether or not the CA was
witnessed, the initial CA rhythm (shockable or nonshockable),
time to ROSC, and use of adrenaline (Table 2). When added to
the basic model, only KYNA and 3-HAA were associated with
poor outcome at 12 months (Table 6). The incremental
models with the addition of KYNA or 3-HAA signiﬁcantly
improved reclassiﬁcation for prediction of 12-month poor
outcome (Table 7).
Discussion
The present study showed that the KP is activated early
after resuscitation from out-of-hospital CA. Patients who
died before ICU discharge exhibited signiﬁcantly higher
levels of KP metabolites at ICU admission compared with
those who survived. All KP metabolite levels predicted ICU
death after resuscitation, whereas KYNA and 3-HAA were
associated with 12-month poor neurological outcome. KP
activation was higher in patients resuscitated from a
nonshockable CA compared with those resuscitated from
a shockable CA.
Table 3. Comparison Between Baseline Characteristics and Kynurenine Pathway Metabolites in the Healthy Volunteers and in
Patients Resuscitated From Cardiac Arrest
Healthy Volunteers
(n=10)
Cardiac Arrest
Patients (n=245)
P Value vs
Healthy
Volunteers ICU Survival (n=198)
P Value vs
Healthy
Volunteers* ICU Death (n=47)
P Value vs
Healthy
Volunteers*
Age, y 63 (59 to 65) 63 (56 to 72) 0.86 63 (56 to 72) 0.98 65 (59 to 75) 0.437
Sex, male,
n (%)
8 (80) 197 (80.4) 1.00 159 (80.3) 1.00 38 (80.6) 1.000
TRP, lmol/L 82.8 (70.0 to 89.0) 39.5 (30.8 to 50.4) <0.0001 40.1 (31.8 to 51.2) <0.0001 37.1 (25.0 to 44.8) <0.0001
KYN, lmol/L 2.4 (2.3 to 2.9) 2.6 (1.8 to 3.5) 0.624 2.4 (1.7 to 3.1) 0.874 3.8 (2.5 to 4.5) 0.003
Ratio of KYN
to TRP
0.03 (0.027 to 0.034) 0.064 (0.045
to 0.089)
<0.0001 0.059 (0.043
to 0.079)
<0.0001 0.095 (0.067
to 0.122)
<0.0001
KYNA, nmol/L 40.6 (32.5 to 60.3) 52.8 (27.5 to 91.8) 0.542 49.2 (26.7 to 83.6) 0.794 90.6 (43.3 to 191.8) 0.058
3-HAA, nmol/L 24.3 (18.1 to 27.8) 28.1 (17.5 to 51.2) 0.277 24.7 (16.7 to 42.4) 0.519 54.6 (28.5 to 104.5) 0.007
Data are reported as median (interquartile range) except as indicated. 3-HAA indicates 3-hydroxyanthranilic acid; ICU, intensive care units; KYN, kynurenine; KYNA, kynurenic acid;
TPR, tryptophan.
*P considered signiﬁcant if <0.025.
DOI: 10.1161/JAHA.114.001094 Journal of the American Heart Association 5
Kynurenine Pathway and Cardiac Arrest Ristagno et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on October 9, 2014http://jaha.ahajournals.org/Downloaded from 
In our population, TRP was signiﬁcantly lower and ratio of
KYN to TRP was signiﬁcantly higher in all resuscitated patients
compared with the 10 healthy volunteers. Of interest is the
observation that levels of KYN, KYNA, and 3-HAA in our
healthy volunteers were not signiﬁcantly different from those
of ICU survivors, although they were signiﬁcantly lower
compared with patients who failed to survive to ICU
discharge. These results are further evidence that early KP
activation, expressed by the ratio of KYN to TRP, is always
present after resuscitation from CA compared with healthy
volunteers. Nevertheless, KP metabolites KYN, KYNA, and 3-
HAA were markedly increased in the instance of poor
outcome, supporting the speciﬁc prognostic role of KP.
KP is a major pathway of the catabolism of the essential
amino acid TRP and is activated during inﬂammation and
tissue injury. On inﬂammatory stimulation, the enzyme
indoleamine 2,3-dioxygenase is induced, and the consequent
KP activation results in degradation of TRP into KYN.9,19 A
systemic inﬂammatory and immune response is observed
after CA, and the magnitude of the inﬂammatory response
correlates with the severity of post-CA circulatory shock and,
ultimately, with outcome.4 The inﬂammatory response is
Table 4. Kynurenine Pathway Activation by Age, Cardiac Arrest Presenting Rhythm, Duration of Cardiac Arrest, and Patient
Characteristics
Variable TRP, lmol/L KYN, lmol/L Ratio of KYN of TRP KYNA, nmol/L 3-HAA, nmol/L
Admission levels
Age, y
<59 38.4 (31.7 to 49.8) 2.2 (1.6 to 3.0) 0.05 (0.04 to 0.08) 42.3 (21.2 to 80.5) 23.9 (17.8 to 49.2)
59 to 68 39.8 (30.9 to 47.9) 2.4 (1.7 to 3.2) 0.06 (0.04 to 0.08) 50.5 (26.7 to 90.6) 29.2 (17.8 to 58.5)
>68 41.1 (28.8 to 51.6) 3.1 (2.4 to 4.1) 0.07 (0.06 to 0.1) 64.6 (37.9 to 100.1) 29.7 (16.9 to 46.1)
P value 0.849 <0.0001 0.0006 0.0298 0.5488
Cardiac arrest presenting rhythm
Shockable 42.4 (34.1 to 53.1) 2.4 (1.7 to 3.2) 0.06 (0.04 to 0.08) 57.3 (38.9 to 100.3) 24.7 (16.9 to 42.0)
Nonshockable 33.1 (24.8 to 42.3) 2.9 (1.7 to 3.2) 0.08 (0.06 to 0.12) 31.6 (15.3 to 82.8) 33.7 (21.4 to 72.4)
P value 0.0001 0.0282 0.0001 0.0001 0.0056
Time to ROSC, min
1 to 15 39.8 (30.4 to 51.3) 2.4 (1.6 to 3.2) 0.06 (0.04 to 0.09) 40.8 (23.9 to 77.6) 22.2 (13.3 to 35.8)
16 to 24 40.2 (29.0 to 50.0) 2.6 (1.8 to 3.9) 0.06 (0.04 to 0.1) 54.6 (29.4 to 93.0) 31.7 (19.8 to 58.6)
25 to 57 38.2 (32.0 to 49.8) 2.6 (2.0 to 3.4) 0.07 (0.05 to 0.08) 57.3 (34.9 to 101.2) 29.8 (18.6 to 59.8)
P value 0.901 0.206 0.185 0.0294 0.0046
Lowest 24-hour systolic blood pressure, mm Hg
≥100 42.4 (33.3 to 57.1) 2.3 (1.7 to 3.1) 0.05 (0.04 to 0.07) 34.9 (20.8 to 83.9) 24.5 (15.0 to 49.3)
70 to 99 39.0 (30.8 to 49.6) 2.5 (1.8 to 3.2) 0.06 (0.04 to 0.09) 52.9 (29.3 to 87.0) 25.8 (17.6 to 44.6)
<70 36.6 (28.3 to 48.4) 3.7 (2.9 to 4.7) 0.1 (0.07 to 0.14) 90.6 (27.2 to 384.8) 66.6 (19.5 to 109.2)
P value 0.156 0.0002 <0.0001 0.0141 0.009
24-hour HCO3, mEq/L
≥20 39.8 (33.1 to 51.6) 2.2 (1.7 to 3.0) 0.05 (0.04 to 0.08) 45.7 (26.6 to 68.9) 24.7 (16.1 to 44.6)
15 to 19 40.1 (29.1 to 50.0) 2.6 (2.0 to 3.7) 0.07 (0.05 to 0.09) 52.8 (26.6 to 99.7) 28.3 (18.6 to 44.4)
<15 33.3 (28.3 to 44.8) 3.2 (2.9 to 4.3) 0.1 (0.07 to 0.16) 95.6 (66.5 to 349.4) 72.4 (28.9 to 119.8)
P value 0.273 <0.0001 <0.0001 <0.0001 0.0001
Outcome at 12 months
Good 39.9 (33.2 to 52.6) 2.2 (1.7 to 3.0) 0.05 (0.040 to 0.08) 49.2 (26.7 to 80.0) 23.6 (16.5 to 38.3)
Poor 39.0 (29.0 to 48.2) 2.9 (2.2 to 4.1) 0.07 (0.06 to 0.1) 58.7 (28.4 to 100.6) 33.9 (17.9 to 66.5)
P value 0.1224 <0.0001 <0.0001 0.046 0.002
Data are reported as median (interquartile range). 3-HAA indicates 3-hydroxyanthranilic acid; KYN, kynurenine; KYNA, kynurenic acid; ROSC, return of spontaneous circulation;
TPR, tryptophan.
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commonly observed after resuscitation from CA and seems to
be related to the duration of ischemia.4 Adrie and colleagues 4
showed that the magnitude of such post-CA inﬂammatory
response is similar to that observed in severe sepsis and
correlates with lactate levels. In their study, however, the
levels of various pro-inﬂammatory cytokines were not inde-
pendent predictors of survival. The ratio of KYN to TRP is
regarded as an indicator of indoleamine 2,3-dioxygenase
activity and has been shown to predict death and severity of
shock in bacteremic patients.18,19 Huttunen et al reported
similar levels of TRP but higher levels of KYN and KYN to TRP
in patients with fatal bacteremia.20
Earlier studies have also reported that elevated concen-
trations of C-reactive protein or other inﬂammatory mediators
(eg, procalcitonin) correlated with patients’ clinical states and
with prediction of survival.21,22 Circulating concentrations of
these biomarkers, however, rise slowly, achieving values
predictive of outcome after 12 to 24 hours following resus-
citation. In the current study, patients exhibiting high KP
activation at ICU admission subsequently had more severe
shock and were more likely to die in the ICU. Accordingly, all
KP metabolites were independent predictors of early death.
More important, KYNA and 3-HAA seem to have the potential
to further predict long-term neurological outcome after CA. At
Table 5. Independent Predictors of Levels of Kynurenine
Pathway Metabolites
Metabolite Variable b P Value
TRP Age 0.539 0.640
Sex (male) 2.731 0.247
Shockable rhythm 8.684 <0.0001
BLS 0.007 0.997
Adrenaline 2.976 0.208
Time to ROSC 0.659 0.629
KYN Age 0.417 0.002
Sex (male) 0.558 0.039
Shockable rhythm 0.263 0.268
BLS 0.428 0.057
Adrenaline 0.653 0.016
Time to ROSC 0.015 0.923
Ratio of KYN to TRP Age 0.264 0.0004
Sex (male) 0.179 0.233
Shockable rhythm 0.506 0.0002
BLS 0.244 0.052
Adrenaline 0.395 0.0092
Time to ROSC 0.014 0.875
KYNA Age 5.276 0.589
Sex (male) 9.476 0.634
Shockable rhythm 40.29 0.022
BLS 24.76 0.136
Adrenaline 50.53 0.012
Time to ROSC 2.037 0.859
3-HAA Age 0.024 0.994
Sex (male) 3.338 0.621
Shockable rhythm 19.76 0.001
BLS 3.005 0.592
Adrenaline 5.981 0.376
Time to ROSC 5.566 0.154
Multivariable linear regression model. 3-HAA indicates 3-hydroxyanthranilic acid; BLS,
bystander-initiated life support; KYN, kynurenine; KYNA, kynurenic acid; ROSC, return of
spontaneous circulation; TRP, tryptophan.
Figure 1. Tryptophan and kynurenine pathway metabolites and
intensive care unit death. Data are reported as median and
interquartile range. Gray dashed lines represent the median
values of each metabolite in healthy volunteers. *P<0.001 vs
survivors. ICU indicates intensive care unit.
Figure 2. Tryptophan and kynurenine pathway and 12-month
death. Data are reported as median and interquartile range. Gray
dotted lines represent the median values of each metabolite in
healthy volunteers. *P<0.02 and **P≤0.001 vs survivors.
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ICU admission, plasma levels of C-reactive protein were still
low and thus were not predictive of outcome.
The KP can be activated in the periphery as well as in the
nervous system. Peripheral KYN readily crosses the blood–
brain barrier and is taken up by glial cells.23 In the central
nervous system further metabolism is segregated and under
physiologic conditions; after the inﬂux of KYN into the brain,
equal amounts of KYNA and 3-HAA are produced.24 These
downstream metabolites, KYNA and 3-HAA, have been
proposed as important modulators of neurologic injury.6
Indeed, 3-HAA exerts neurotoxic actions by inducing
both cerebral oxidative stress and excitotoxicity through
activation of N-methyl-D-aspartate receptors, whereas KYNA
has neuroprotective properties related to its activity as an
N-methyl-D-aspartate antagonist.25 In patients with stroke, KP
activation has been shown to correlate with stroke severity
Table 6. Multivariable Logistic Models for the Prediction of ICU Mortality and 12-Month Poor Outcome
OR 95% CI P Value
ICU death
TRP 0.994 per 1 lmol/L increase 0.970 to 1.018 0.614
KYN 1.431 per 1 lmol/L increase 1.136 to 1.803 0.002
KYN to TRP 1.665 per 1 SD increase 1.143 to 2.426 0.0079
KYNA 1.005 per 1 nmol/L increase 1.002 to 1.007 0.0007
3-HAA 1.013 per 1 nmol/L increase 1.005 to 1.021 0.0015
12-month poor outcome
TRP 1.007 per 1 lmol/L increase 0.985 to 1.030 0.519
KYN 1.249 per 1 lmol/L increase 0.982 to 1.588 0.069
KYN to TRP 1.251 per 1 SD increase 0.798 to 1.963 0.329
KYNA 1.004 per 1 nmol/L increase 1.001 to 1.008 0.0139
3-HAA 1.011 per 1 nmol/L increase 1.001 to 1.022 0.0272
3-HAA indicates 3-hydroxyanthranilic acid; ICU, intensive care unit; KYN, kynurenine; KYNA, kynurenic acid; OR, odds ratio; TRP, tryptophan.
Table 7. Comparison Between the Basic Model and the Incremental Models With the Addition of Kynurenine Pathway Metabolites
for Prediction of ICU Death and 12-Month Poor Outcome
ROC-AUC DROC-AUC (SE) P Value cfNRI (SE) P Value
ICU death
Basic model 0.78
TRP 0.78 0.001 (0.004) 0.788 0.20 (0.16) 0.21
KYN 0.83 0.046 (0.017) 0.009 0.50 (0.16) 0.002
KYN to TRP 0.81 0.023 (0.012) 0.016 0.46 (0.16) 0.005
KYNA 0.83 0.051 (0.021) 0.015 0.54 (0.16) 0.001
3-HAA 0.82 0.042 (0.020) 0.037 0.65 (0.16) <0.0001
12-month poor outcome
Basic model 0.83
TRP 0.84 0.003 (0.002) 0.256 0.04 (0.13) 0.738
KYN 0.84 0.005 (0.006) 0.383 0.11 (0.13) 0.392
KYN to TRP 0.83 0.000 (0.003) 0.975 0.07 (0.13) 0.588
KYNA 0.84 0.012 (0.008) 0.114 0.26 (0.12) 0.046
3-HAA 0.84 0.009 (0.007) 0.212 0.31 (0.12) 0.017
D indicates the difference in ROC-AUC between the basic model and the model with the addition of kynurenine pathway metabolites; 3-HAA indicates 3-hydroxyanthranilic acid;
cfNRI, category-free net reclassiﬁcation index; KYN, kynurenine; KYNA, kynurenic acid; ROC-AUC, area under the receiver operating characteristic curve; TRP, tryptophan.
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and cerebral infarct size.6 Brouns showed that the ratio of
KYN to TRP on hospital admission correlated with poor
functional outcome at 3 months.26 In the present study, the
ratio of KYN to TRP was higher in patients with a poor
outcome at 12 months, and the absolute levels were
comparable to those reported by Brouns and Darlington (ie,
between 0.04 and 0.09).6,26
Interestingly, in our study, both KYNA and 3-HAA increased
similarly, and their increases were more signiﬁcant in the
instances of longer duration of CA and, thereby, greater
ischemic insult. Although KYNA generation might represent a
protective adaptive response to overcome the neurotoxic
effects resulting from 3-HAA,25 the ratio of KYNA to 3-HAA
was not signiﬁcantly different in patients who survived
compared with those who died and did not correlate with
outcomes (data not shown). Accordingly, relationships
between KYNA and 3-HAA and between KYNA and neuropro-
tection still are not fully understood. Patients resuscitated
from nonshockable CA showed greater activation of the KP,
having signiﬁcantly higher levels of all KP metabolites but
lower neuroprotective KYNA compared with patients resusci-
tated from shockable CA.
In sepsis, high KP activity is associated with the severity of
shock and with a vasopressor requirement.5 Level of KP
activation, expressed as the ratio of KYN to TRP, in our study
was comparable to KP activation in septic patients with a
fairly low requirement for inotropes. Inotrope requirement
during post-CA syndrome care is generally fairly low, and high
requirement correlates with poor outcome.27 In contrast, in
stroke patients, it is intriguing that hypotension is uncommon
despite high activation of the KP.28 This ﬁnding contrasts with
the hypothesis that activation of the KP per se causes
vasodilatory shock and hypotension. We cannot deﬁne
whether KP activation after CA is an epiphenomenon or a
causative pathway involved in postresuscitation severe hypo-
tension and, ultimately, in outcome. Nevertheless, additional
evidence of the involvement of the KP in cardiovascular
pathology has been reported recently in 3224 patients
suffering from stable coronary artery disease.8 In these
patients, KP activation was a strong predictor of occurrence of
major coronary events, acute myocardial infarction, and
cardiovascular mortality.8 The interplay among shock, neuro-
logical damage, and systemic inﬂammation seems to be
complex, and further studies should examine where organ-
speciﬁc activation of the KP occurs.
We limited our study to patients with blood samples, who
represented approximately half of the whole data set of the
FINNRESUSCI study.14 Some differences existed between the
245 patients included in the study and the 303 not included,
and patients with blood samples were somewhat less severely
ill than those without blood samples. Nevertheless, early KP
activation was consistently observed after resuscitation in
patients who presented poor early and long-term outcome.
The strengths of this study include the sample size, which
makes it one of the largest biohumoral studies in out-of-
hospital CA; the prospective acquisition of clinical data; and
the determination of outcome performed prospectively by a
qualiﬁed independent assessor.
In conclusion, higher levels of KP metabolites at ICU
admission are associated with hypotension during the ﬁrst
24 hours after resuscitation and with ICU death in out-of-
hospital CA patients. In addition, KYNA and 3-HAA indepen-
dently predict poor 12-month neurological outcome. Further
studies may elucidate whether the KP contributes to post-CA
syndrome and whether it may be amenable to targeted
therapeutic interventions.
Appendix
Finnresusci Investigators
The FINNRESUSCI Laboratory Study Group: Participating
hospitals, investigators (Inv.) and study nurses (SN.) in the
FINNRESUSCI study.
Satakunta Central Hospital, Dr Vesa Lund (Inv.), P€aivi
Tuominen, Satu Johansson, Pauliina Perkola, Elina Kumpulai-
nen (SN.); East Savo Central Hospital, Dr Markku Suvela
(Inv.), Sari Hirvonen, Sirpa Kauppinen (SN.); Central Finland
Central Hospital, Dr Raili Laru-Sompa (Inv.), Mikko Reilama
(SN.); South Savo Central Hospital, Dr Heikki Laine (Inv.),
Pekka Kettunen, Iina Smolander (SN.); North Carelia Central
Hospital, Dr Matti Reinikainen (Inv.), Tero Surakka (SN.);
Sein€ajoki Central Hospital, Dr Kari Saarinen (Inv.), Pauliina
L€ahdeaho, Johanna Soini (SN.); South Carelia Central Hos-
pital, Dr Seppo Hovilehto (Inv.); Vaasa Central Hospital, Dr
Simo-Pekka Koivisto, Dr Raku Hautam€aki (Inv.); Kanta-H€ame
Central Hospital, Dr Ari Alasp€a€a (Inv.), Tarja Heikkil€a (SN.);
Lappi Central Hospital, Dr Outi Kiviniemi (Inv.), Esa Lintula
(SN.); Keski-Pohjanmaa Central Hospital, Dr Tadeusz Kamin-
ski (Inv.), Jane Roiko (SN.); Kymenlaakso Central Hospital, Dr
Seija Alila, Dr Jussi Pentti (Inv.), Reija Koskinen (SN.); L€ansi-
Pohja’s Central Hospital, Dr Jorma Heikkinen (Inv.) Helsinki
University Hospital, Jorvi Hospital, Dr Jukka Vaahersalo, Dr
Tuomas Oksanen, Dr Tero Varpula (Inv.), Anne Eronen,
Teemu Hult, Taina Nieminen (SN.); Meilahti Hospital Medical
ICU, Dr Tom B€acklund (Inv.), Leevi Kauhanen (SN.); Meilahti
Hospital ICU, Dr Kirsi-Maija Kaukonen, Dr Ville Pettil€a (Inv.),
Leena Pettil€a, Sari Sutinen (SN.); Tampere University Hospi-
tal, Dr Sanna Hoppu, Dr Jyrki Tenhunen, Dr Sari Karlsson
(Inv.), Atte Kukkurainen, Simo Varila, Samuli Kortelainen,
Minna-Liisa Peltola (SN.); Kuopio University Hospital, Dr
Pamela Hiltunen, Dr Jouni Kurola, Dr Esko Ruokonen (Inv.),
Elina Halonen, Saija Rissanen, Sari Rahikainen (SN.); Oulu
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University Hospital, Dr Risto Ahola, Dr Tero Ala-Kokko (Inv.),
Sinikka S€alki€o (SN.)
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